Recent pr, imo, is another brick in the wall and not the finished product. The company isn't pr'ing to sell shares but to inform. There is a difference... a diversified immuno-onc portfolio being built to justify a co-development deal for an IND which could look like an upfront multi-million payment along w/ a milestone payment schedule or a license deal on IP patents held. a license in the 100 mil range could hit here at any time imo.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.